Crossmark

Retrospective Analysis of Diagnostic and Prognostic Value of Serum Glypican-3 in Patients With HCV-Related Cirrhosis With Or Without HCC After Achieving SVR With DAA Treatment

Crossref DOI link: https://doi.org/10.1007/s12029-025-01371-0

Published Online: 2026-01-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Caviglia, Gian Paolo

Guariglia, Marta

Gaia, Silvia

Troshina, Yulia

Rolle, Emanuela

Saba, Francesca

Dileo, Eleonora

Carucci, Patrizia

Ciancio, Alessia
Funding

Funding for this research was provided by:

Università degli Studi di Torino
License Information

Text and Data Mining valid from 2026-01-09

Version of Record valid from 2026-01-09
More Information

Article History

Accepted: 7 December 2025

First Online: 9 January 2026

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of “A.O.U. Città della Salute e della Scienza di Torino—A.O. Ordine Mauriziano—A.S.L. Città di Torino” (protocol code 0008732, approval date 26 January 2022).

: Informed consent was obtained from all patients involved in the study.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below